个股
共 6,296 份研报 · 国内 4,037 · 国外 1,841
Kaiser铝业:风险回报逐渐改善——近期表现不佳后上调至中性评级
Kaiser Aluminum (KALU): Risk / Reward Becoming More Favorable - Upgrade to Neutral Following Recent Underperformance
摩根大通·2026-10-26·12 页·美股
IDFC第一银行:2027财年第二季度核心趋势符合预期,资产回报率扩张持续受益于正向经营杠杆;维持增持评级
IDFC First Bank: 2QFY27: In-line core trends, RoA expansion continues on positive operating leverage; remain OW
摩根大通·2026-10-26·16 页·其它
摩根大通 - Flagstar银行:2026年第三季度——面临挑战的季度,再次因EPS展望重置及受监管租金问题受到审视
Flagstar Bank (FLG) — 3Q26: Challenging Qtr on Another EPS Outlook Reset & Rent Regulated Comes Under the Microscope Again
摩根大通·2026-10-26·16 页·美股
微软前沿巡演强化对Copilot势头的信心
Microsoft Frontier Tour Reinforces Confidence in Copilot Momentum
花旗·2026-10-26·11 页·美股
IDE849二线治疗中位总生存期达17.4个月,全球安全性数据更新进一步巩固该DLL3 ADC的竞争力
IDEAYA Biosciences Inc (IDYA.O) IDE849's 17.4-Month 2L mOS and Global Safety Update Further Strengthen Competitive DLL3 ADC Profile
花旗·2026-10-26·11 页·美股
Arrivent Biopharma(AVBP.O):CDH17在转移性结直肠癌中轻松突破约30%客观缓解率门槛,未来与贝伐珠单抗联合有望进一步提升客观缓解率
Arrivent Biopharma Inc. (AVBP.O): CDH17 Handily Beats ~30% ORR Bar in mCRC, Future Combo With Bev Positioned to Push ORR Higher
花旗·2026-10-26·13 页·美股
苏伊士(EXHO.PA):2026财年:转型信号明确,我们仍需观察业务稳定化的更具体证据
Sodexo (EXHO.PA): FY26: Convincing message on the turnaround. We wait to see more tangible evidence of stabilisation of the business.
花旗·2026-10-26·13 页·其它
诺华对雷米布鲁替尼持乐观态度:预计复发型多发性硬化症销售额超40亿美元、慢性自发性荨麻疹/慢性诱导性荨麻疹亦超40亿美元
Novartis AG (NOVN.S): Novartis upbeat remibrutinib. Sees $4bn+ in RMS $4bn+ in CSU/CIndU. SPMS, HS, food allergy additional
花旗·2026-10-26·11 页·其它
Solutions(7202.SE)2026年第三季度:销售额超出指引,同比增长10%;2026财年增长存在轻微上行风险
Solutions (7202.SE) 3Q26: Sales ahead of guidance at +10%; slight upside risk to FY26 growth
花旗·2026-10-26·12 页·其它
NOBA Bank Group(NOBA.ST):模型更新
NOBA Bank Group (NOBA.ST): Model Update
花旗·2026-10-26·12 页·其它
IDEAYA生物科学公司(IDYA.O):IDE849二线治疗17.4个月中位总生存期及全球安全性更新进一步强化其DLL3 ADC的竞争定位
IDEAYA Biosciences Inc (IDYA.O): IDE849's 17.4-Month 2L mOS and Global Safety Update Further Strengthen Competitive DLL3 ADC Profile
花旗·2026-10-26·11 页·美股
Centrica PLC(CNA.L):天然气管网并购前景如何?
Centrica PLC (CNA.L): Gas network M&A on the horizon?
花旗·2026-10-26·13 页·其它
Arrivent Biopharma(AVBP.O):CDH17在转移性结直肠癌中显著超越约30%的ORR基准,未来与贝伐珠单抗联合有望进一步提升ORR
Arrivent Biopharma Inc. (AVBP.O): CDH17 Handily Beats ~30% ORR Bar in mCRC, Future Combo With Bev Positioned to Push ORR Higher
花旗·2026-10-26·13 页·美股
A2牛奶公司(A2M.AX):H&H季度表现支持a2的战略布局
The A2 Milk Company Ltd (A2M.AX): H&H quarterly supports a2's strategy
花旗·2026-10-26·13 页·其它
中集来福士:烟台船厂投资者日核心要点
CIMC Raffles: Key takeaways from Investor Day at Yantai Shipyard
高盛·2026-10-26·6 页·港股
潍柴动力(000338.SZ/2338.HK):向AI数据中心发电增长曲线迁移
Weichai Power (000338.SZ/2338.HK): Transitioning to AIDC power generation growth
高盛·2026-10-26·11 页·A股
2026年三季度业绩回顾:内销保持稳定,出口逐步回暖;维持"买入"评级
ZHEJIANG SUPOR CO. (002032.SZ): 3Q26 Earnings Review: Stable domestic and recovering export; Buy
北京高华证券·2026-10-26·8 页·A股
思源电气(002028.SZ):2026年三季度营业利润符合预期,一次性损益致净利润偏低,尽管面临监管挑战美国订单仍持续流入
Sieyuan Electric (002028.SZ): First Take: 3Q26 OP in line, NP below on one-offs, with continued US order intakes despite regulatory
北京高华证券·2026-10-26·10 页·A股
润泽科技(300442.SZ):简评:AI资本开支激增将加速高ROIC基建转型;2026年三季度收入确认时点因素导致业绩不及高盛预期
Range Intelligent (300442.SZ): First Take: AI Capex Surge to Accelerate Higher-ROIC Infra Transformation; 3Q26 Missed GSe on Sales Timing
北京高华证券·2026-10-26·8 页·创业板
培生(PSON.L):2026年前9个月业绩审视:业绩稳健,各板块趋势分化但集团整体预测基本维持不变,聚焦业务重组
Pearson (PSON.L): 9M26 results review: Solid print with group estimates broadly unchanged despite mixed segment trends; focus on re-segmentation
高盛·2026-10-26·11 页·其它
显示 3441 - 3460 条,共 6,296 条